MedTrace Logo

Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)

NCT02272270 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-06-19

No results posted yet for this study

Summary

This will be an open label, single arm study. Subjects with newly diagnosed high grade glioma will begin minocycline one week prior to beginning postoperative chemoradiation and continue it until progression, intolerance, or the end of adjuvant temozolomide, whichever comes first.

Conditions

  • Newly Diagnosed High Grade Glioma

Interventions

DRUG

Minocycline with chemoradiation (temozolomide and radiation therapy)

Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-27
Primary Completion
2017-03-08
Completion
2018-02-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02272270 on ClinicalTrials.gov